NCT03219528View on ClinicalTrials.gov

A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing

PHASE4CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 13, 2018

Primary Completion Date

February 28, 2024

Study Completion Date

February 28, 2024

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Rifaximin 550 MG

Rifaximin 550 mg three times daily for 14 days

OTHER

Low FODMAP Diet

Low FODMAP dietary intervention for 4 weeks

Trial Locations (1)

48109

University of Michigan, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Michigan Institute for Clinical and Health Research (MICHR)

UNKNOWN

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Michigan

OTHER

NCT03219528 - A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing | Biotech Hunter | Biotech Hunter